Transcriptional Regulators of the Malarial var Multigene Family
疟疾变种多基因家族的转录调节因子
基本信息
- 批准号:8088124
- 负责人:
- 金额:$ 20.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-06-15 至 2013-05-31
- 项目状态:已结题
- 来源:
- 关键词:Affinity ChromatographyAntibodiesAntigenic VariationBindingBiochemicalBiologicalCell NucleusCellsCellular biologyCessation of lifeChromosomesClinicalCollaborationsDNADevelopmentDrug usageEpitopesErythrocytesExperimental DesignsFluorescent in Situ HybridizationGene ExpressionGenesGenetic TechniquesGenomeGoalsHumanImmune responseImmunochemistryIn VitroInfectionInvadedLaboratoriesMalariaMass Spectrum AnalysisMembrane ProteinsMethodologyMethodsMolecularMolecular BiologyMultigene FamilyNamesNucleic Acid Regulatory SequencesNutrientParasitesPlasmodium falciparumPlasmodium falciparum erythrocyte membrane protein 1PlayPopulationPrincipal InvestigatorPromoter RegionsProtein BindingProtein CProteinsProteomeReagentRegulationRepressionResearchResearch PersonnelResearch Project GrantsResistanceRoleSiteStaining methodStainsTEV proteaseTetanus Helper PeptideTimeTranscription CoactivatorTranscription Repressor/CorepressorTransfectionTransgenic OrganismsVariantVirulenceVirulence Factorschromatin immunoprecipitationcrosslinkin vivointerestlink proteinnovel strategiespromoterpublic health relevancetooltranscription factoruptakevector
项目摘要
DESCRIPTION (provided by applicant): The goal of this research project is to develop a new approach that combines chromatin immunoprecipitation, tandem affinity purification and mass spectrometry to identify possible activators and/or repressors of the var multigene family encoding the malaria virulence factor, Plasmodium falciparum erythrocyte membrane protein 1, PfEMP1. During their intraerythrocytic development, malaria parasites switch expression to alternative forms of this variant surface protein to evade the host immune response. The genome of each P. falciparum parasite contains approximately 60 var genes distributed on different chromosomes. However, only one var gene is expressed by each parasite in a mutually exclusive manner. The promoter region of var genes plays an important role in this regulation and it is believed that this mechanism might involve specialized repressor (PfVPR) and/or activator (PfVPA) molecules. The specific aims of the current proposal include experimental designs and methods, some newly developed in our laboratories for P. falciparum such as tandem affinity purification and fluorescent in situ hybridization (FISH). They are: Aim I. To identify PfVPA and PfVPR regulators of var gene expression by chromatin immunoprecipitation, tandem affinity purification and mass spectrometry; and Aim II. To initiate a functional analysis of the PfVPA and PfVPR proteins in P. falciparum.
PUBLIC HEALTH RELEVANCE: Malaria parasites invade and ultimately destroy circulating red blood cells of their host, often leading to severe clinical illness or death. During their intraerythrocytic development, malaria parasites switch expression to alternative forms of a variant surface protein PfEMP1 encoded by the var genes to evade the host immune response. The goal of this research collaboration is to combine tools and techniques from genetics, molecular biology, and immunochemistry, and the expertise of two laboratories to unravel the molecular determinants of antigenic variation during malaria infection.
描述(由申请人提供):本研究项目的目标是开发一种结合染色质免疫沉淀、串联亲和纯化和质谱的新方法,以鉴定编码疟疾毒力因子、恶性疟原虫红细胞膜蛋白1 (PfEMP1)的var多基因家族可能的激活因子和/或抑制因子。在它们的红细胞发育过程中,疟疾寄生虫转换表达这种变体表面蛋白的替代形式以逃避宿主的免疫反应。每个恶性疟原虫的基因组包含大约60个变异基因,分布在不同的染色体上。然而,每个寄生虫只有一个var基因以互斥的方式表达。var基因的启动子区域在这一调控中起着重要作用,据信这一机制可能涉及特异性抑制因子(PfVPR)和/或激活因子(PfVPA)分子。本提案的具体目标包括实验设计和方法,其中一些是我们实验室新开发的恶性疟原虫的串联亲和纯化和荧光原位杂交(FISH)。目的:利用染色质免疫沉淀、串联亲和纯化和质谱技术鉴定PfVPA和PfVPR基因表达调控因子;和Aim II。启动恶性疟原虫PfVPA和PfVPR蛋白的功能分析。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Structure, function and inhibition of the phosphoethanolamine methyltransferases of the human malaria parasites Plasmodium vivax and Plasmodium knowlesi.
人类疟原虫疟原虫的磷酸乙醇胺甲基转移酶的结构,功能和抑制作用。
- DOI:10.1038/srep09064
- 发表时间:2015-03-12
- 期刊:
- 影响因子:4.6
- 作者:Garg A;Lukk T;Kumar V;Choi JY;Augagneur Y;Voelker DR;Nair S;Ben Mamoun C
- 通讯作者:Ben Mamoun C
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHOUKRI BEN MAMOUN其他文献
CHOUKRI BEN MAMOUN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHOUKRI BEN MAMOUN', 18)}}的其他基金
Fosinopril analogs for the treatment of human babesiosis
福辛普利类似物用于治疗人类巴贝虫病
- 批准号:
10396069 - 财政年份:2021
- 资助金额:
$ 20.7万 - 项目类别:
Fosinopril analogs for the treatment of human babesiosis
福辛普利类似物用于治疗人类巴贝虫病
- 批准号:
10211812 - 财政年份:2021
- 资助金额:
$ 20.7万 - 项目类别:
Fosinopril analogs for the treatment of human babesiosis
福辛普利类似物用于治疗人类巴贝虫病
- 批准号:
10594970 - 财政年份:2021
- 资助金额:
$ 20.7万 - 项目类别:
Antigen Discovery and Vaccine Development for Human Babesia Parasites
人类巴贝虫寄生虫的抗原发现和疫苗开发
- 批准号:
10386919 - 财政年份:2020
- 资助金额:
$ 20.7万 - 项目类别:
Antigen Discovery and Vaccine Development for Human Babesia Parasites
人类巴贝虫寄生虫的抗原发现和疫苗开发
- 批准号:
10163799 - 财政年份:2020
- 资助金额:
$ 20.7万 - 项目类别:
Antigen Discovery and Vaccine Development for Human Babesia Parasites
人类巴贝虫寄生虫的抗原发现和疫苗开发
- 批准号:
10609400 - 财政年份:2020
- 资助金额:
$ 20.7万 - 项目类别:
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment
用于疟疾治疗的 Kalihinol 支架的 Hit-to-Lead 开发
- 批准号:
9789813 - 财政年份:2018
- 资助金额:
$ 20.7万 - 项目类别:
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment
用于疟疾治疗的 Kalihinol 支架的 Hit-to-Lead 开发
- 批准号:
10228612 - 财政年份:2018
- 资助金额:
$ 20.7万 - 项目类别:
Development of endochin-like quinolones for babesiosis therapy
用于治疗巴贝虫病的类内啡肽喹诺酮类药物的开发
- 批准号:
9392521 - 财政年份:2016
- 资助金额:
$ 20.7万 - 项目类别:
Probing the natural genomic diversity of Babesia microti
探究田鼠巴贝虫的自然基因组多样性
- 批准号:
9064063 - 财政年份:2015
- 资助金额:
$ 20.7万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 20.7万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 20.7万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 20.7万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 20.7万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 20.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 20.7万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 20.7万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 20.7万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 20.7万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 20.7万 - 项目类别: